A single-dose study to investigate the effects of 3 different doses of inhaled AZD2115 in COPD patients

Study identifier:D3060C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, double-blind, placebo and active controlled, multi-centre, 6 way cross-over, single-dose Phase IIa study to investigate the local and systemic effects of 3 different doses of inhaled AZD2115 in patients with chronic obstructive pulmonary disease (COPD)

Medical condition

COPD

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD2115, Placebo, Indacaterol, Indacaterol + Tiotropium

Sex

All

Actual Enrollment

39

Study type

Interventional

Age

40 Years +

Date

Study Start Date: 01 Mar 2012
Primary Completion Date: 01 Oct 2012
Study Completion Date: 01 Oct 2012

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2012 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria